Quote:Perhaps there is an additive or synergistic effect with the anti-angiogenic Avastin… and/or the chemo?
Great analysis and discussion, Sherlock/Jake—this is exactly why I keep coming back to IH.
We might be looking at a powerful additive or synergistic effect here when combining leronlimab with Avastin (anti-angiogenic) and/or standard chemotherapy. I remember years ago RP discussing how leronlimab could act as a therapeutic multiplier—boosting chemo's efficacy so we can scale back doses and spare patients from brutal toxicities. That concept was incredibly exciting then, and I believe the clinical data will ultimately bear it out.
What I really hope to see from the I-SPY and PRE-I-SPY trials is leronlimab moving into earlier lines of therapy. If it can show strong standalone efficacy early on, the valuation of this asset will skyrocket simply because the addressable market is massive.
Think about Dr. Kasi’s enthusiasm when treating late-stage, heavily pre-treated patients. Now, imagine the medical community's reaction if leronlimab outperforms the current Standard of Care (SOC) in healthier, early-stage patients by reactivating their innate immune response. Even if it "only" matches current SOC efficacy, its pristine safety profile and synergistic potential to lower chemo toxicity make it a massive win.
The challenge has never been leronlimab's therapeutic potential; it's been proving it to the FDA with undeniable biomarker data. Hopefully, the upcoming Creatv MicroTech results will finally deliver the airtight data we need to make our case.
17
